| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Ticagrelor | Ethyl 2-(((3aS, 4R, 6S, 6aR)-6-(2-ethoxy-2-oxoethoxy)-2, 2-dimethyltetrahydro-3aH-cyclopenta[d][1, 3]dioxol-4-yl)amino)acetate | VE0010914 | View |
| Ticagrelor | Ethyl 2-(((3aS, 4R, 6S, 6aR)-6-amino-2, 2-dimethyltetrahydro-3aH-cyclopenta[d][1, 3]dioxol-4-yl)oxy)acetate oxalate | VE0010916 | View |
| Ticagrelor | Ethyl 2-(((3aS, 4R, 6S, 6aR)-6-hydroxy-2, 2-dimethyltetrahydro-3aH-cyclopenta[d][1, 3]dioxol-4-yl)amino)acetate | VE0010915 | View |
| Ticagrelor | S-Propyl-2-thiobarbituric Acid | VE0010911 | View CAS 145783-12-6 |
| Ticagrelor | Tert-butyl 2-(((3aS, 4R, 6S, 6aR)-6-amino-2, 2-dimethyltetrahydro-3aH-cyclopenta[d][1, 3]dioxol-4-yl)oxy)acetate | VE0010919 | View |
| Ticagrelor | Ticagrelor Amine Impurity | VL3180008 | View CAS 1902184-02-4 |
| Ticagrelor | Ticagrelor DP3 | VE006279 | View CAS 1251765-07-7 |
| Ticagrelor | Ticagrelor EP Impurity C | VL3180018 | View CAS 1616703-93-5 |
| Ticagrelor | Ticagrelor EP Impurity G | VL3180006 | View |
| Ticagrelor | Ticagrelor EP Impurity H | VL3180004 | View |
| Ticagrelor | Ticagrelor IP Impurity D | VL3180005 | View |
| Ticagrelor | Ticagrelor IP Impurity H | VL3180007 | View |
| Ticagrelor | Ticagrelor Impurity 15 | VE007040 | View |
| Ticagrelor | Ticagrelor Impurity 23 | VE007033 | View CAS 1345413-20-8 |
| Ticagrelor | Ticagrelor Impurity 70 | VE007039 | View CAS 1808068-84-9 |
| Ticagrelor | Ticagrelor Impurity 81 | VE0011566 | View CAS 1006376-62-0 |
| Ticagrelor | Ticagrelor Pyrimidine Dimer | VL3180013 | View |
| Ticagrelor | Ticagrelor Related Compound -01 | VL3180015 | View CAS 155899-66-4 |
| Ticagrelor | Ticagrelor Related Compound 101 | VE0011560 | View CAS 2376278-69-0 |
| Ticagrelor | Ticagrelor Related Compound 27 (Oxalate Salt) | VE0011557 | View CAS 1816939-47-5 |
| Ticagrelor | Ticagrelor Related Compound 28 | VE007035 | View CAS 220352-36-3 |
| Ticagrelor | Ticagrelor Related Compound 76 | VL3180016 | View |
| Ticagrelor | Ticagrelor Related Compound 91 | VE0011555 | View CAS 2376278-68-9 |
| Ticagrelor | Ticagrelor Related Compound 94 | VE007034 | View CAS 1427524-53-5 |
| Ticagrelor | Ticagrelor Related Compound A | VE006280 | View CAS 220352-38-5 |
| Ticagrelor | Ticagrelor Triazole Isomer | VL3180014 | View |
| Ticagrelor | Ticagrelor Triol Impurity | VL3180001 | View CAS 220347-05-7 |
| Ticagrelor | Ticagrelor related compound B | VL3180019 | View CAS 1788033-05-5 |
| Ticagrelor | Ticagrelor sulfoxide (Mixture of Diastereomers) | VL3180011 | View CAS 1644461-85-7 |
| Ticagrelor | ent-Ticagrelor | VE009338 | View CAS 2096989-55-6 |
| Ticagrelor | 2-(((3aS, 4R, 6S, 6aR)-6-Amino-2, 2-dimethyltetrahydro-4H-cyclopenta[d][1, 3]dioxol-4-yl)oxy)ethan-1-ol | VE0011563 | View CAS 2165881-71-8 |
| Ticagrelor | 4, 6-Dichloro-2-propylsulfanyl-pyrimidine | VE0010912 | View |
| Ticagrelor | 4, 6-Dichloro-5-nitro-2-(propylthio)pyrimidine | VE0010913 | View CAS 145783-14-8 |
| Ticagrelor | 6-Chloro-5-nitro-2-(propylthio)pyrimidin-4(1H)-one | VE0010730 | View CAS 1548397-10-9 |
| Ticagrelor | (1R, 2R)-2-(3, 4-Difluorophenyl)-cyclopropanamine | VE0011565 | View CAS 1414348-35-8 |
| Ticagrelor | (1R, 2S)-2-(3, 4-Difluorophenyl)cyclopropanamine (2R)-hydroxy(phenyl)ethanoate | VE0011278 | View CAS 376608-71-8 |
| Ticagrelor | (1R, 2S)-2-(3, 5-Difluorophenyl)cyclopropanamine | VE0011554 | View CAS 220352-50-1 |
| Ticagrelor | (1S, 2S)-2-(3, 4-Difluorophenyl)-cyclopropanamine | VE0011567 | View CAS 1459719-81-3 |
Ticagrelor Related Compound
Ticagrelor is a kind of antiplatelet medication. It improves the flow of blood via your veins. This implies that your blood is less prone to form a hazardous blood clot. If you have an elevated risk of blood clots, using ticagrelor can help avoid them.
References
- Dobesh, Paul P., and Julie H. Oestreich. “Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety.” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol. 34, no. 10, Aug. 2014, pp. 1077–90, https://doi.org/10.1002/phar.1477. Accessed 8 Mar. 2023.
- Tomaniak, Mariusz, et al. “Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes.” JAMA Cardiology, vol. 4, no. 11, Nov. 2019, p. 1092, https://doi.org/10.1001/jamacardio.2019.3355. Accessed 8 Mar. 2023.
- HIGHLIGHTS of PRESCRIBING INFORMATION. www.accessdata.fda.gov/drugsatfda_docs/label/2016/022433s020lbl.pdf.
FAQ
What is the mechanism of action of ticagrelor?
Ticagrelor is a P2Y12-receptor antagonist that is used orally. In vitro investigations have shown that ticagrelor binds to the P2Y12 receptor reversibly and noncompetitively at a location different from that of the endogenous agonist adenosine diphosphate (ADP).
Why is ticagrelor taken with aspirin?
Ticagrelor in combination with aspirin decreased the rates of the composite endpoint of cardiovascular mortality, myocardial infarction (MI), and stroke more efficiently than clopidogrel in combination with aspirin among patients with acute coronary syndromes (ACS) in the PLATO study.
What is the indication for ticagrelor?
Ticagrelor is prescribed to patients with the acute coronary syndrome (ACS) or a history of myocardial infarction to lower the risk of cardiovascular mortality, myocardial infarction, and stroke (MI).
